Document:

exv10w13

 

Exhibit 10.13

MASTER SERVICES AGREEMENT

     THIS Master Services Agreement (the “Agreement”) is effective as of the 28th
day of October, 2004, (the “Effective Date”), by and between i3 Research, a division of Ingenix
Pharmaceutical Services (UK) Limited. (“Ingenix”), with offices at Sygnus Court, 22-32 Market
Street, Maidenhead, Berkshire, UK SL6 8AD, and Corcept Therapeutics Incorporated (“Sponsor”), with
offices at 275 Middlefield Road, Suite A, Menlo Park, CA 94025.

     WHEREAS, Sponsor is engaged in research and development of pharmaceutical products; and

     WHEREAS, Ingenix is engaged in providing services to pharmaceutical manufacturers in support
of their clinical research and product development activities;

     WHEREAS, Sponsor wishes to retain Ingenix, from time to time, to assist in certain product
development activities relating to certain of Sponsor’s clinical studies (each of which shall be
referred to as a “Study”); and

     WHEREAS, Sponsor agrees to compensate Ingenix for its services.

     NOW THEREFORE, in consideration of the premises and the mutual promises and undertakings
herein contained, the parties agree as follows:

SECTION 1 — Services — General

1.1 Sponsor hereby retains Ingenix to provide the services (the “Services”) that are described in
written task orders (“Task Orders”, a form of which is attached to this Agreement as Exhibit A)
which are executed by the parties from time to time. The parties acknowledge and agree that their
respective Affiliates may execute Task Orders under this Agreement. In that event, such
Affiliate(s) shall be bound by all terms and conditions of this Agreement and the applicable Task
Order, and entitled to all rights and protections afforded Sponsor or Ingenix under this Agreement.
While this Agreement creates certain obligations between the parties, it does not create an
obligation on the part of Sponsor or any Sponsor Affiliate to engage Ingenix to provide services,
or an obligation on the part of Ingenix or any Ingenix Affiliate to provide services; such
obligations shall arise only upon the execution of a Letter of Intent (a form of which is attached
hereto as Exhibit B), a Task Order, or a written amendment to a Task Order (a “Change Order”, a
form of which is attached hereto as Exhibit C). The terms of this Agreement shall be made a part of
and incorporated by reference into each Task Order and each Task Order is incorporated and made a
part of this Agreement. In the event of a conflict between the terms of this Agreement and a Task
Order, the terms of this Agreement will govern, unless otherwise agreed in a Task Order.

1.2 “Affiliate” means, when associated with a party to this Agreement, any entity that controls, is
controlled by or is under common control with, that party. “Control” means the possession, directly
or indirectly, of at least 50% of the share capital or voting rights or of the power to direct or
cause the direction of the management and policies of an entity, whether through the ownership of
voting securities, by contract or otherwise.

1.3 Each Task Order shall constitute a unique agreement and shall stand alone with respect to any
other Task Order entered into under this Agreement. To the extent required under Title 21 CFR Part
312.52 in the United States, and any equivalent laws of other countries, the parties shall document
separately in writing the transfer by Sponsor to Ingenix of any of Sponsor’s responsibilities. In
the absence of such a separate document, the description of Services provided in the relevant Task
Order shall be deemed the required written transfer of obligations from Sponsor to i3 Research for
that Study. Notwithstanding the foregoing, Sponsor will retain the ultimate authority and control
over and

1

 

responsibility for each Study. Sponsor shall retain and have responsibility for all Study
activities not specifically transferred to Ingenix. The parties acknowledge and agree that Sponsor
shall at all times be deemed to be the “sponsor” of each study pursuant to the terms of the U. S.
Federal Food, Drug and Cosmetic Act, as from time to time amended, the regulations of the U.S. Food
and Drug Administration (“FDA”), as promulgated in the Title 21 of U.S. Code of Federal
Regulations, and any equivalent laws of other countries.

1.4 The terms of a Task Order may be amended or modified by mutual written agreement of Ingenix and
Sponsor. If Sponsor wishes (i) to change the timelines, deliverables or scope or scale of the
Services covered by a Task Order, (ii) to obtain additional services not initially covered by a
Task Order, or (iii) to reduce or remove any of the Services covered by a Task Order, Sponsor shall
so advise Ingenix. If Ingenix believes a change in the scope or scale of Services is necessary or
advisable, Ingenix shall so advise Sponsor. The parties will negotiate diligently and in good faith
the proposed revisions to the timelines, deliverables, scope or scale of Services and the
professional fees and costs for performing changed or additional services or for reducing or
removing Services, and shall execute a Change Order to the applicable Task Order. In the event
Ingenix provides additional services or expends resources, at Sponsor’s written request and in
strict accordance with Sponsor’s requirements, in the absence of a Change Order, Sponsor will
compensate and/or reimburse Ingenix for all fees and reasonable costs incurred.

1.5 The parties shall perform their obligations under this Agreement and each Task Order in
accordance with the terms of this Agreement, the applicable Task Order, applicable provisions of
the Study protocol, agreed upon Standard Operating Procedures; the current Guidelines for Good
Clinical Practice (“GCP Guidelines”); the Declaration of Helsinki of the 41st World Medical
Assembly, South Africa 1996 as amended; and applicable local laws and regulations.

1.6 Neither party shall have any obligation of exclusivity of any nature to the other, or any
obligation to conduct, sponsor, or to offer to conduct or sponsor, any particular services or study
or any number of studies, unless specified in a Task Order. Each party shall be free to provide
services to or conduct or sponsor clinical or research studies involving other parties, so long as
a party’s agreement with any such third party does not prevent it from performing its obligations
under this Agreement or a Task Order. Each party understands and agrees that the other party or
its Affiliates may be in a business similar to or offer products or services the same as the other
party (or one or more of its Affiliates) and may already have developed, be in the process of
developing, or plan to develop products, services and information similar to those owned or
developed by the other. Nothing contained herein shall be construed to prohibit a party from so
doing as long as it does so independently and without using Confidential Information disclosed by
the other.

1.7 During the term of this Agreement Ingenix shall maintain all materials and all other data
obtained or generated by Ingenix in the course of providing the Services, including all
computerized records and files (“Work Product”), in a secure area reasonably protected from fire,
theft and destruction. At the expiration or termination of this Agreement and each Task Order
Sponsor shall provide Ingenix with written instructions as to the disposition of the Work Product
obtained or generated by Ingenix in the course of providing the applicable Services. Such written
instructions will provide that Ingenix (a) deliver the Work Product, in the form in which Ingenix
currently holds them, to a designated Sponsor location or to such other entity or at such other
address as Sponsor may specify, (b) retain the Work Product for the period of time specified in the
Task Order, or (c) dispose of the Work Product, except for those portions which Ingenix is required
by law or regulation to store or maintain. After termination of this Agreement or the applicable
Task Order, storage, destruction, shipping and other services relating to the final record
disposition will be billed as Pass — through Expenses (as defined below) to Sponsor.
Notwithstanding the foregoing, Ingenix may retain copies of any of the Work Product as are
reasonably necessary for regulatory or insurance purposes, subject to its ongoing obligation to
maintain the confidentiality of such materials.

2

 

SECTION 2 — Institution/Investigator — Services

2.1 The parties acknowledge that Ingenix’ Services under a Task Order may include identifying
potential medical institutions (“Institutions”) or clinical investigators (“Investigators”) and/or
negotiating, executing and/or administering contracts with them governing their conduct of the
Study (“Study Agreements”). If, pursuant to a Task Order, Sponsor delegates to Ingenix the
responsibility for negotiating and/or executing Study Agreements, the following provisions will
apply:

	 	(a)  	Sponsor may provide Ingenix with a list of suggested Institutions and/or
Investigators to be recruited by Ingenix for a Study. Ingenix shall notify Sponsor in
writing as to any listed Institution or Investigator with which Ingenix does not wish
to contract.
	 
	 	(b)  	Selection of all Institutions or Investigators will be subject to approval by
Sponsor, in writing, prior to initiation of any Study-related activities involving that
Institution/Investigator or the start of any negotiations with such
Institution/Investigator.
	 
	 	(c)  	Each Study Agreement shall be fully consistent with this Agreement and the
applicable Task Order. The Study Agreement used with each Institution and Investigator
will be in substantially the form attached hereto as Exhibit D, and subject to approval
in advance by Sponsor. All changes to such form agreement suggested by an Investigator
will require Sponsor’s prior review and approval.
	 
	 	(d)  	Sponsor will provide Ingenix with a current form of Power of Attorney, as
required, for each country in which the Study will be conducted.
	 
	 	(e)  	If an Institution/Investigator requests indemnification from Sponsor, Sponsor
will issue a letter of indemnification directly to the Institution/Investigator.
Sponsor acknowledges that Ingenix shall have no indemnification obligation to any
Institution/Investigator relative to the Study drug or the applicable Study protocol.
	 
	 	(f)  	Ingenix will administer payments to Institutions/Investigators from funds
provided in advance by Sponsor to Ingenix for that purpose. Ingenix will disburse
payments to Institutions/Investigators on behalf of Sponsor according to the provisions
of the Study Agreement and the applicable Task Order. Ingenix will not be liable for
payments not made on a timely basis to any Institution/Investigator as a result of
Sponsor’s failure to provide, in advance, sufficient funds for such payments. Ingenix
will promptly return to Sponsor any funds received from Sponsor for payments to
Institutions/Investigators which are remaining as unpaid or unpayable at the expiration
or other earlier termination of this Agreement or any Task Order.

2.2 The parties acknowledge and agree that, for the purposes of this Agreement or any Task Order,
Institutions/Investigators shall not be considered as employees, agents or subcontractors of
Ingenix or of Sponsor and that Investigators will be required to exercise their own independent
medical judgement. Ingenix’ responsibilities with respect to Institutions/Investigators shall be
limited to those specifically set forth in the applicable Task Order.

SECTION 3 — Compensation and Expenses

3.1 As compensation for providing the Services, Sponsor shall pay Ingenix professional fees in the
amounts and upon the terms specified in one or more attachments to the applicable Task Order. Each
Task Order will include as attachments a study budget containing Ingenix’ estimated professional
fees and Pass-through Expenses (“the Budget”), a payment schedule (the “Payment Schedule”) and a
timeline showing performance milestones (the “Timeline”). If the assumptions under which the
parties created the Budget, the Payment Schedule or the Timeline prove to be inaccurate, in whole
or in part, or if matters reasonably beyond the control of the parties detrimentally affect a
Study, then the parties shall review

3

 

each of the Budget, the Payment Schedule and the Timeline and incorporate reasonable revisions in a
Change Order to the applicable Task Order.

3.2 Sponsor will reimburse Ingenix for reasonable travel and other reasonable out-of-pocket
expenses incurred by Ingenix personnel identified in the Budget or at the request of Sponsor
(“Pass-through Expenses”), unless Ingenix expressly agrees in advance to waive such reimbursement.
Pass-through Expenses shall include the following:

	 	(a)  	Travel via commercial airlines (using coach class or the equivalent), train or
rental car;
	 
	 	(b)  	Local travel to places other than Ingenix’ office by personal car at a rate to
be agreed between the parties for each country;
	 
	 	(c)  	Actual and reasonable lodging and meal expenses;
	 
	 	(d)  	Actual and reasonable expenses for telephone, mail, express courier, facsimile,
storage and photocopying services, and any other communication or technology expenses
incurred in the performance of the Services under this Agreement; and
	 
	 	(e)  	Payments to third party vendors, consultants and independent contractors,
including, upon the prior written consent of Sponsor, payments to outside legal counsel
relating to review of Study Agreements in countries other than the U.K.

Ingenix shall submit a reasonably detailed invoice with copies of receipts attached of such
expenses to Sponsor on a monthly basis.

3.3 Professional fees and estimated Pass-through Expenses, as indicated in the applicable Budget,
shall be exclusive of value added tax (“VAT”), except where VAT is irrecoverable by Ingenix.

3.4 All invoices and payments will be stated and made in Euros unless otherwise provided for in the
applicable Task Order. If Ingenix performs Services whereby it incurs costs or expenses in a
currency different than Euros or another currency specified in a Task Order, Ingenix shall have the
option of invoicing Sponsor for such costs and expenses in Euros after applying the applicable
exchange spot rate published in the Financial Times on the last business day of the relevant
invoice period to the initial currency. Sponsor will pay each invoice, via check or wire transfer
of immediately available funds, within 30 days of receipt of the invoice.

3.5 In the event Sponsor disputes one or more items in an invoice, Sponsor will notify Ingenix in
writing within fifteen (15) business days of receipt of the invoice and such notice shall contain a
reasonably specific description of the item(s) being disputed and the basis therefor. Ingenix will
respond to Sponsor within fifteen (15) business days of receipt of the notification. This written
communication pattern will continue until Ingenix has provided Sponsor with sufficient
justification for the disputed item(s) or until the parties agree to a resolution of the disputed
amount. Sponsor shall pay the undisputed portion of the invoice within thirty (30) days of receipt
of the invoice and shall use commercially reasonable best efforts to pay the disputed amount within
fifteen (15) days of resolution of the dispute. In the event the parties are unable to reach a
satisfactory resolution within one hundred eighty (180) days of the original invoice, either party
can submit the dispute to binding arbitration in accordance with Section 9.2 of this Agreement.

SECTION 4 — Confidentiality

4.1 Each party acknowledges that in connection with the performance of the Services, it may
receive, learn or have access to confidential, trade secret, or proprietary information concerning
the other party or third parties to whom the other party has an obligation of confidentiality
(“Confidential Information”).

4

 

4.2 Sponsor’s Confidential Information shall include, without limitation, information regarding the
Sponsor’s business; drug products and proposed drug products; current or proposed studies on
Sponsor’s products; prior research and results of studies on Sponsor’s drug products; and reports
and decisions resulting from clinical trials on Sponsor’s drug products. Ingenix Confidential
Information shall include, without limitation, business information; information regarding Ingenix
services and documentation; Ingenix’ business methodologies and processes and associated
algorithms, tools, programs, software architecture, including but not limited to source codes, and
technology.

4.3 Each party agrees that (a) it will use the other party’s Confidential Information only as may
be necessary in connection with the Services; (b) it will treat such information as confidential
and proprietary; (c) without the prior written consent of the other party it will not disclose such
information orally or in writing to any third party (except however, to disclose such information
to its respective agents or representatives, IRB/Ethics Committee members, or the FDA or other
regulatory authorities, all of whom have a need to know such information in connection with the
purpose for which it is disclosed to the party); (d) it will take all reasonable precautions to
protect the Confidential Information; and (e) it will not otherwise appropriate such information to
its own use or to the use of any other person or entity. Without limiting the foregoing, each
party agrees to take at least such precautions to protect the other party’s Confidential
Information as it takes to protect its own Confidential Information. Upon termination of this
Agreement, each party will return to the other party or certify as destroyed all tangible items
containing any of the other party’s Confidential Information that are held by that party or its
employees, agents or contractors. However, each party may retain archive copies of information as
required by applicable regulatory requirements. Each party agrees to notify the other party if it
becomes aware of any unauthorized use or disclosure of the other party’s Confidential Information.

4.4 If either party believes it is required by law or by a subpoena or court order to disclose any
of the other party’s Confidential Information, it shall promptly notify the other party prior to
any disclosure and shall make all reasonable efforts to allow the other party an opportunity to
seek a protective order or other judicial relief.

4.5 Nothing in this Agreement shall be construed to restrict disclosure or use of information that
(a) was in the possession of or rightfully known by the recipient, without an obligation to
maintain its confidentiality, prior to receipt from the other party; (b) is or becomes generally
known to the public without violation of this Agreement; (c) is obtained by the recipient in good
faith from a third party having the right to disclose it without an obligation of confidentiality;
(d) is independently developed by the receiving party without reference to the other party’s
Confidential Information; or (e) is required by law to be disclosed.

4.6 Each party agrees not to disclose or utilize individual patient or medical claim information in
any way that would violate any physician-patient confidence or any state or federal laws or
regulations.

4.7 Except as required by law neither party shall disclose Sponsor’s retention of Ingenix for
professional services or the terms of this Agreement or any Task Order, unless each party has
agreed in writing that such disclosure may be made.

4.8 The terms of this Section 4, and the parties’ obligations hereunder, shall survive termination
or expiration of this Agreement and the completion of Ingenix’ Services hereunder.

SECTION 5 — Term and Termination

5.1 This Agreement shall commence on the Effective Date and, unless otherwise terminated, shall
continue until the later of [three (3)] years from the Effective Date or the completion of Services
for all Task Orders entered into within that [three (3)] year period. Each Task Order shall take
effect as of an effective date designated in the Task Order and, unless otherwise terminated, shall
continue until either the date specified therein as the expiration date or until the Services
specified in the Task Order have

5

 

been completed. Termination of this Agreement or of any Task Order shall not affect any other Task
Order; each Task Order shall continue in full force and effect until its expiration date or
completion of the Services, unless specifically earlier terminated in accordance with the terms of
this Agreement or the terms of that Task Order.

5.2 In the event that either party commits a breach or defaults in any of the terms or conditions
of this Agreement or a Task Order, and that party fails to remedy the default or breach within
sixty (60) days after receipt of notice of the default or breach from the other party, the party
giving notice may, at its option, immediately terminate this Agreement, or the Task Order, as
applicable, at the end of the 60-day notice period.

5.3 Sponsor shall have the right to terminate this Agreement or a Task Order (for other than
default or breach by Ingenix) at any time by giving appropriate written notice at least forty-five
(45) days prior to the desired termination date.

5.4 Ingenix shall have the right to terminate this Agreement or a Task Order (for other than
default or breach by Sponsor) at any time by giving appropriate written notice at least one hundred
eighty (180) days prior to the desired termination date.

5.5 Either party shall have the right to terminate this Agreement and/or one or more Task Orders at
any time upon receipt of written notice to the other party, if the other party shall be adjudicated
insolvent or shall petition for or consent to any relief under any insolvency, re-organization,
receivership, liquidation, compromise, or any moratorium statute, whether now or hereafter in
effect, or shall make an assignment for the benefit of its creditors, or shall petition for the
appointment of a receiver, liquidator, trustee, or custodian for all or a substantial part of its
assets, or if a receiver, liquidator, trustee or custodian is appointed for all or a substantial
part of its assets and is not discharged within thirty (30) days after the date of such
appointment. In the event that any of the above events occur, that party shall immediately notify
the other, in writing, of its occurrence.

5.6 Ingenix may, upon fifteen (15) days prior written notice to Sponsor, terminate a Task Order or
cease performing its obligations thereunder, without such cessation resulting in an Ingenix breach
or default, if Sponsor fails to make payment to Ingenix as required by such Task Order.

5.7 Upon termination of this Agreement or any Task Order the parties will reasonably cooperate with
each other to provide for an orderly cessation of Ingenix’ Services. Ingenix shall use its
commercially reasonable best efforts to minimize costs associated with the cessation of the
Services. In the event Sponsor terminates only part of the Services described in a Task Order, the
parties will cooperate in good faith to enter into a Change Order amending the terms of that Task
Order accordingly. In the event the Agreement or any of the Services is terminated Ingenix will be
entitled to receive payment for all work and services performed by it and expenses incurred or
irrevocably committed to third parties up to the effective date of termination. In addition,
Sponsor shall pay all reasonable fees and expenses incurred by Ingenix that are necessary or
reasonably required in connection with the orderly cessation of the Services. If a Study, Task
Order, or the Agreement is cancelled or terminated before the Services have been performed
completely, Ingenix shall refund to Sponsor any funds advanced to Ingenix for fees and costs not
yet incurred or due to the extent that the payments for the liabilities associated with such fees
or costs can reasonably be avoided in whole or in part.

5.8 Upon the termination of this Agreement or a Task Order for any reason, and payment by Sponsor
of all amounts owed to Ingenix, Ingenix shall arrange for the return to Sponsor of unused supplies
of the Study drug and all other materials of Sponsor in Ingenix’ possession or control.

SECTION 6 — Delays, Suspension and Correction of Work

6.1 In the event Sponsor provides Ingenix with a written detailed notification of a material error
by Ingenix or any employee thereof, in the performance of Ingenix’ Services under a Task Order,
where Ingenix does not dispute the existence of such material error and such notice is provided in
a timely

6

 

manner following completion or performance of the Services relating to such material error, Ingenix
shall have the option of taking the following steps:

(a) Ingenix can correct the material error free of charge to Sponsor as soon as reasonably
possible, or

(b) Ingenix can retain a third party reasonably acceptable to Sponsor to correct the
material error for which Ingenix will pay the cost, or

(c) Ingenix can accept reduced payment by an amount to be mutually determined by the
parties.

     If Ingenix disputes the existence of a material error, the notice from Sponsor is not provided
in a timely manner, or the parties cannot agree upon any of the above options, then the provisions
of this Agreement relating to dispute resolution shall apply. This section shall not affect
Sponsor’s right to terminate this Agreement if it considers the material error a breach of this
Agreement that is not cured.

6.2 Ingenix will be responsible for and will not seek compensation from Sponsor for additional
fees, costs and expenses it incurs due to errors or delays to the extent that such errors or delays
are found to be the direct result of Ingenix’ failure to perform its required obligations under
this Agreement or the relevant Task Order. Sponsor will not hold Ingenix responsible for and will
compensate Ingenix appropriately for additional fees, costs and expenses incurred by Ingenix due to
errors or delays to the extent that such errors or delays (a) are found to result from (i) the
failure of Sponsor to perform its obligations or provide necessary documents, materials, records,
direction or cooperation as may be required of it during the course of the performance of this
Agreement or a Task Order, or (ii) Sponsor undertaking any action or activity or failing to
undertake an action or activity so that Ingenix is or would be prohibited from the due observance
or performance of any material covenant, condition or agreement contained in this Agreement or a
Task Order, and such action or inaction continues for a period of thirty (30) days after Ingenix
gives Sponsor written notice thereof, or (b) are not the direct result of Ingenix’ failure to
perform.

6.3 In the event the start or progress of a clinical trial that is the subject of a Task Order is
delayed for unavoidable or justified reasons, or in the event Sponsor delays, suspends or places a
hold on the Study for any reason, Sponsor shall promptly provide Ingenix with written notice of
such delay, hold or suspension and Sponsor and Ingenix will, within 30 days of such notice, on
appropriate revisions to the applicable Task Order and each party will complete its respective
duties and obligations as described in any such resulting Change Order. During the period
following Ingenix’ receipt of Sponsor’s notice of delay, hold or suspension Sponsor will compensate
Ingenix for additional professional fees and pass-through expenses incurred by Ingenix as a result
of such delay or suspension, as agreed to and set forth in any such resulting Change Order.

6.4 The parties agree that, in the event a delay, hold or suspension exceeds thirty (30) days, and,
in the case of a delay, such delay is not caused solely by Ingenix, Ingenix shall have the right,
in its sole discretion, to re-deploy its personnel assigned to the Study unless Sponsor and Ingenix
agree to appropriate compensation to Ingenix for maintaining the personnel assigned to the Study.

SECTION 7 — Indemnification

7.1 Sponsor agrees to indemnify and hold harmless Ingenix, its affiliates and their respective
officers, directors, employees, agents and other representatives against claims, expenses, or
losses resulting from Ingenix’ provision of the Services, a Study drug, any study conducted
pursuant hereto, or this Agreement or any Task Order except to the extent such claims, expenses or
losses result from Ingenix’ negligence or wilful misconduct.

7.2 Ingenix agrees to indemnify and hold harmless Sponsor, its affiliates and their respective
officers, directors, employees, agents and other representatives against claims, expenses or losses
resulting from

7

 

Ingenix’ negligence or wilful misconduct, except to the extent that such claims result from
Ingenix’ actions taken at the direction of Sponsor.

7.3 Ingenix’ indemnification obligation hereunder shall not apply to any claim which is caused in
whole or in meaningful part by (i) the negligence, malpractice or intentional misconduct of
Sponsor, any clinical investigator or laboratory or their respective personnel, Institutional
Review Board/Ethics Committee or its members, any person or entity affiliated with any clinical
site, or any independent contractor engaged to provide drug labelling, packaging, storage and
shipment services and all such persons and entities shall not be considered affiliates, agents or
employees of Ingenix for the purposes of this Agreement; or (ii) the administration of a Study drug
or an individual’s participation in any study.

7.4 Each party’s obligations under Section 7 of this Agreement are further conditioned upon the
indemnified party giving the indemnifying party timely written notice and assistance in the defence
of any claim, proceeding or investigation; provided however, that failure of the indemnified party
to give such notice shall not limit the indemnified party’s right to indemnification except in such
case where such failure materially and adversely affects the indemnifying party’s ability to defend
against such claim, proceeding or investigation.

7.5 Neither party will enter into any settlement agreement that attributes fault or negligence to
the other party, requires any payment by the other party, or restricts the future actions or
activities of the other party, without the other party’s prior written consent.

7.6 Under no circumstances will either party be responsible under this Agreement or a Task Order
for any indirect, incidental, special or consequential damages resulting from either party’s
performance or failure to perform under this Agreement. In addition, in no event shall the
collective, aggregate indemnification liability of Ingenix, its Affiliates and their respective
directors, officers, employees, agents and representatives under this Agreement exceed the amount
of fees actually received by Ingenix from Sponsor for the tasks or services performed from which
such liability arose.

7.7 In the event Ingenix incurs costs in excess of $1,000 USD as a result of its becoming involved
in or being required to appear or participate with respect to a matter relating to a Sponsor study
drug that is the subject of litigation, arbitration or some other dispute resolution mechanism, and
where Ingenix’ performance of the Services is not at issue, Sponsor shall reimburse Ingenix for
such costs. The parties agree to cooperate with each other and to use commercially reasonable best
efforts in good faith to minimize Ingenix’ in and the costs relating to such disputes.

SECTION 8 — Representations and Warranties

8.1 Each party represents that it is authorized to enter into this Agreement, and any Task Order
issued hereunder, and that the terms of this Agreement are not inconsistent with or a violation of
any contracted or other legal obligation to which it is subject.

8.2 Each party represents that in performing under this Agreement and each Task Order it shall (a)
conduct business in conformance with sound ethical standards of integrity and honesty and in
compliance with all applicable laws, regulations and guidelines; (b) conduct business in such a way
as to not give the appearance of impropriety, even when the behaviour or activity is in compliance
with the law; and (c) not achieve business results by illegal act or unethical conduct.

8.3 Sponsor represents that it has all necessary or appropriate qualifications, authorizations,
licenses or permits as the sponsor who is responsible for the marketing of a new drug.

8.4 Ingenix represents and warrants that neither it nor any Ingenix employee who will perform
Services has been debarred under Section 306(a) or 306(b) of the U. S. Federal Food, Drug and
Cosmetic Act, or any equivalent law of another country, and no debarred person will in the future
be employed or utilized to perform any Services. To the best of Ingenix’ knowledge, no person
performing any Services, including any investigator, has a conviction which could lead to debarment
under Section

8

 

306(a) or Section 306(b) or any equivalent law of another country. Ingenix agrees to notify
Sponsor immediately of any action known to it toward conviction or debarment of any person
performing any Services.

SECTION 9 — Dispute Resolution

9.1 Sponsor and Ingenix recognize that a bona fide dispute may arise under this Agreement or a Task
Order which may relate to either party’s rights and/or obligations hereunder. Sponsor and Ingenix
agree that they shall use all commercially reasonable efforts to resolve, in an amicable manner,
any dispute that may arise.

9.2 If the parties cannot resolve their dispute within thirty (30) days, Sponsor or Ingenix may at
such time initiate arbitration under the Commercial Dispute Resolutions Rules of the American
Arbitration Association then in effect.

9.3 Notwithstanding the above, the complaining party reserves the right to seek injunctive or other
relief in a court of competent jurisdiction if it believes that immediate relief is necessary to
protects its business interests.

SECTION 10 — Force Majeure

     Neither Sponsor or Ingenix shall be liable for delays in performing or any failure to perform
any of the terms of this Agreement or a Task Order caused by the effects of fire, strike, war
(declared or undeclared), insurrection, acts of terror, government restriction or prohibition,
force majeure or other causes reasonably beyond its control and without its fault, but the party
failing to perform shall use all reasonable endeavour to resume performance of this Agreement as
soon as feasible. Any episode of force majeure which continues for 60 days from the date of
notification of its existence shall give the non-affected party the right to terminate this
agreement upon 30 days additional notice.

SECTION 11 — Patents, Rights in Work Product and Trade Secrets

11.1 Any invention, discovery, or improvement related to Sponsor’s products or technology which is
conceived or reduced to practice as a direct consequence of Ingenix’ performance of the Services
hereunder (the “Inventions”) shall become Sponsor property and shall be used by Sponsor as Sponsor
deems appropriate. Ingenix agrees to execute and have executed assignments of the Inventions to
Sponsor, along with other documents that be necessary or helpful to Sponsor in filing patent
applications, or which may relate to any litigation or interference and/or controversy in
connection therewith. The entire control, prosecution, and conduct of any patent application filed
by Sponsor shall be outside the jurisdiction of and without expense to Ingenix and its officers,
employees, representatives and agents. Ingenix acknowledges that Sponsor has the exclusive right
to file patent applications in connection with the Inventions. Ingenix warrants that neither it,
nor its employees, agents and representatives, will prevent Sponsor from filing patent applications
for, or from applying the results of the research carried out for Sponsor hereunder.

11.2 All reports, data, technical information, original works of authorship and all other
information, furnished by or on behalf of Sponsor, or created for Sponsor as part of the Services
rendered hereunder, shall be the sole property of Sponsor.

11.3 Sponsor acknowledges that all computer programs, applications, databases, methods, techniques,
processes and other materials and ideas used by Ingenix in performance of the work under this
Agreement, and not supplied to Ingenix by Sponsor (“Ingenix Works”), are the exclusive property of
Ingenix or its licensors. Sponsor agrees that any improvements, alterations or enhancements to the
Ingenix Works during the term of this Agreement or the Study shall be the sole property of Ingenix.
In no event shall Ingenix be precluded from use of its general knowledge, skills and experience,
and any of its ideas, concepts, know-how and techniques used or developed by it in the course of
providing Services under this Agreement.

9

 

SECTION 12 — Disclaimer

12.1 Sponsor acknowledges that the results of the Studies for which the Services are to be provided
hereunder are inherently uncertain and that, accordingly, there can be no assurance, representation
or warranty by Ingenix that the product covered by this Agreement can, either during the term of
this Agreement or thereafter, be successfully developed or, if so developed, will receive the
required approval by the regulatory authorities.

12.2 Sponsor acknowledges that Ingenix will provide professional services hereunder and not a
product. The terms of this Agreement exclude all implied warranties including but not limited to
the implied warranties of merchantability and fitness for a particular purpose.

12.3 Sponsor acknowledges that Ingenix will require documents, drug supplies, data, records and
cooperation of Sponsor to perform the Services and that Ingenix is not responsible for delays or
other consequences arising from Sponsor’s failure to provide such documents, drug supplies, data,
records or cooperation.

12.4 Sponsor acknowledges that the Services to be provided by Ingenix hereunder are based upon
information supplied by both Ingenix and Sponsor, among other elements, and that Ingenix does not
guarantee or warrant such Services to any specifications, functions or other standards, except as
outlined in this Agreement and/or its Exhibit(s).

12.5 Sponsor acknowledges that the development of the protocol concept and scientific rationale
shall be the sole responsibility of Sponsor regardless of Ingenix’ involvement or lack thereof.

SECTION 13- Employees

     Ingenix’ staff are not, nor shall they be deemed to be at any time during the term of this
Agreement, the employees of Sponsor. Sponsor agrees that neither it nor its Affiliates shall
directly or indirectly solicit for employment, employ or otherwise retain staff of Ingenix during
the term of this Agreement nor within the period of twelve (12) months following termination of
this Agreement.

SECTION 14 — Communications and Payments

     14.1 All communications provided for in this Agreement shall be in English and sent by
registered first class mail, postage prepaid, return receipt requested, addressed to the respective
parties as follows:

     To Sponsor:

Corcept Therapeutics Incorporated

275 Middlefield Road, Suite A

Menlo Park, CA 94025

ATTN: Robert Roe, MD

Tel: (650) 688-8812

Fax: (650) 327-3218

     To Ingenix:

Ingenix Pharmaceutical Services (UK) Limited

Sygnus Court

22-32 Market Street

Maidenhead, Berkshire

UK SL6 8AD

ATTN: Nigel Page

10

 

     With a copy to:

Ingenix Pharmaceutical Services, Inc.

12125 Technology Drive

Eden Prairie, Minnesota 55344

ATTN: General Counsel

Tel: (952) 833-7211

Fax: (952) 833-7201

     14.2 All payments to be made to Ingenix by Sponsor shall be in Euros. Payments made via
cheque shall be sent to the above UK address. Payments to be made by Sponsor via bank transfer of
immediately available funds shall be sent to the following bank account:

NatWest Bank

66 High Street

Maidenhead

Berkshire

UK

Account: 06670571

Sort code: 60-00-04

SWIFT: NWB KGB 2L

SECTION 15 — Miscellaneous

15.1 The parties hereto are independent contractors. Nothing in this Agreement or any Task Order
is intended or shall be deemed to constitute a partnership, franchise or joint venture relationship
between the parties. Neither party shall incur any debts or make any commitments for the other
except to the extent, if at all, specifically provided for in this Agreement, a Task Order or as
otherwise authorized in writing

15.2 Neither party shall have the right to assign this Agreement or any of the rights or
obligations hereunder without the prior written consent of the other party, except that (a) Ingenix
may subcontract with such individuals or entities it deems necessary and appropriate in order to
perform the Services, and (b) either party may assign this Agreement to an Affiliate or a successor
to that area of its business to which this Agreement is related, upon prior written notice, where
such Affiliate or successor has the financial and operational capacity and ability to perform the
assigning party’s obligations hereunder.

15.3 Ingenix shall maintain complete and accurate records relating to its performance of the
Services and pass-through expenses incurred in connection therewith. During the term of this
Agreement and for one year thereafter or until a U.S. NDA for a Study relating to a Task Order is
filed, whichever is later, Sponsor or Sponsor’s designee may, upon reasonable notice and at
Sponsor’s sole cost and expense, audit Ingenix’ records, facilities or procedures related to
Ingenix’ provision of the Services under this Agreement or a Task Order. Sponsor agrees to hold
such records and procedures in confidence. Audits shall be conducted by Sponsor on site at
Ingenix, in a manner designed to cause the least interruption to Ingenix’ business operations, and
shall occur no more than once per year.

15.4 If any provision of this Agreement is found by a court to be voided, invalid or unenforceable,
the same shall either be reformed to comply with applicable laws and regulations or stricken if not
so conformable, so as not to affect the validity or enforceability of the remaining provisions of
this Agreement, except if the principal intent of this Agreement is frustrated by such reformation
or deletion in which case this Agreement shall terminate.

15.5 Unless the parties otherwise agree, any document that is provided in connection with this
Agreement or a Task Order must be (a) in English, or (b) accompanied by a certified English
translation, in which case the English translation shall prevail unless the document is a statutory
or other official document.

11

 

15.6 The parties hereto acknowledge that each has read this Agreement, understands it and agrees to
be bound by its terms. The parties agree that this Agreement, along with each Task Order, is the
complete agreement between the parties on the subject matter and supersedes all proposals (oral or
written), understandings, representations, conditions, warranties, covenants and other
communications between the parties relating to the same subject matter.

15.7 The terms, provisions, representations and warranties contained in this Agreement that, by
their sense and context are intended to survive the performance thereof by either party or both
parties hereunder, shall so survive the completion of performance, expiration or termination of
this Agreement.

15.8 This Agreement shall be interpreted and enforced in accordance with the laws of England and
Wales and each party hereby specifically consents to the personal jurisdiction thereof.

15.11 This Agreement may be executed in counterparts, each of which shall be deemed an original but
all of which taken together shall constitute one and the same instrument.

     IN WITNESS WHEREOF, the following have caused this Master Services Agreement to be executed by
their respective duly authorized representatives effective as of the Effective Date.

	 	 	 	 	 	 	 
	CORCEPT THERAPEUTICS INCORPORATED	 	 	 	INGENIX PHARMACEUTICAL
	

	 	 	 	 	 	SERVICES (UK) LIMITED
	 
	 	 	 	 	 	 
	By:

	 	          /s/ Robert L. Roe
	 	By:
	 	          /s/ Alex Kordonsky
	

	 	 
	 	 	 	 
	Title:

	 	                    President
	 	Title:
	 	          Global Controller / Director of Finance
	

	 	 
	 	 	 	 
	Date:

	 	          02 November 2004
	 	Date:	 	 
	

	 	 	 	 	 	 

LIST OF EXHIBITS:

EXHIBIT A: Form of Task Order

EXHIBIT B: Form of Letter of Intent

EXHIBIT C: Form of Change Order

12

 

MASTER SERVICES AGREEMENT: EXHIBIT A

FORM OF TASK ORDER

     THIS
Task Order is made and entered into to be effective as of the
___ day of ___,
___ by and between Corcept Therapeutics Incorporated. (“Sponsor”) and Ingenix Pharmaceutical
Services (UK) Limited (“Ingenix”).

     WHEREAS, Sponsor and Ingenix have entered into that certain Contract Research Organization
Master Agreement dated the ___ day of ___,
200___ (hereinafter referred to as the “CRO Master
Agreement”); and

     WHEREAS, pursuant to the CRO Master Agreement, Ingenix has agreed to perform certain Services
in accordance with Task Orders from time to time entered into by the parties, as more fully
provided in Section 1 of the CRO Master Agreement, and Sponsor and Ingenix now desire to enter into
such a Task Order.

     WHEREAS,
Ingenix and Sponsor desire that Ingenix provide certain services with respect to a                                          
                                                             
 (the “Study”) for the study of the drug                                                             
(“Study Drug”) as set out in the Protocol titled:
                                        .

     NOW, THEREFORE, in consideration of the mutual covenants contained herein, the parties hereby
agree as follows:

     1. Scope of Services. Ingenix shall perform the services described in the Scope of
Services, attached to this Task Order as Attachment A, and any other documents attached to this
Task Order (“Services”).

     2. Compensation. For performance of these Services, Sponsor shall pay to Ingenix the
amounts set forth in the Budget set forth in Attachment B to this Task Order, which amounts shall
be payable pursuant to the Payment Schedule set forth in Attachment C to this Task Order.

     3. Term and Termination. The term of this Task Order shall commence upon the
effective date stated above and shall continue until [state a specific date or completion of
Services as described in Attachment B], provided, however, the provisions of the CRO Master
Agreement shall govern its termination prior to completion.

     4. Incorporation by Reference; Conflict. The provisions of the CRO Master Agreement
are hereby expressly incorporated by reference into and made a part of this Task Order. In the
event of a conflict between the terms and conditions of this Task Order and those of the CRO Master
Agreement, the terms of this Task Order shall take precedence and control over those of the CRO
Master Agreement.

     5. Notices. Any Notices given hereunder shall also be sent by fax, with a
confirmation copy sent via first class United States mail, as follows, in addition to those noted
in the CRO Master Agreement:

{To be specified in each Task Order}

     6. Timely Completion. The timeline for this Task Order is attached as Attachment D.

     IN WITNESS WHEREOF, the parties have hereunto signed this Task Order effective as of the day
and year first written above.

13

 

	 	 	 
	

	 	CORCEPT THERAPEUTICS INCORPORATED
	 
	 	 
	

	By:	 
	 
	 	 
	

	Its:	 
	 
	 	 
	

	Date: 	 
	 
	 	 
	

	INGENIX PHARMACEUTICAL
	

	SERVICES (UK) LIMITED
	 
	 	 
	

	By:	 
	 
	 	 
	

	Its:	 
	 
	 	 
	

	Date: 	 

LIST OF ATTACHMENTS FOR EACH TASK ORDER:

	 
	ATTACHMENT A:          SCOPE OF SERVICES

	ATTACHMENT B:          BUDGET

	ATTACHMENT C:          PAYMENT SCHEDULE

	ATTACHMENT D:          TIMELINE

14

 

MASTER SERVICES AGREEMENT: EXHIBIT B

FORM OF LETTER OF INTENT

15

 

MASTER SERVICES AGREEMENT: EXHIBIT C

FORM OF CHANGE ORDER

	 	 	 	 	 	 
	 	Sponsor:

	 	 	Effective Date of CO:	 
	 	Sponsor Contact:

	 	 	Project Code:	 
	 	Sponsor Tel:

	 	 	Agreement and all prior COs:	 
	 	Project Director:

	 	 	PACT No.:	 
	 	Project Manager:

	 	 	Protocol No.:	 
	 	Therapeutic Area:

	 	 	Financial Analyst:	 
	 	Account Director:
	 	 	 	 
	 

This Change Order is
effective as of the date identified above, by and between Sponsor and i3
Research and shall be incorporated into and become a part of the Agreement. Except as amended
hereby, the terms and conditions of the Agreement, including those relating to invoicing and
payment, shall remain in full force and effect.

Describe Requested Change In Scope of Services

	 	 	 
	1.

	 	 
	2.

	 	 
	3.

	 	 

Fees and/or Expenses associated with Change In Scope

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	Agreement	 	 	Revised Agreement	 	 	 	 
	 	 	 	 	Value prior to this	 	 	Value Including	 	 	Variance	 
	 	Description of Fees or expense	 	 	Change Order	 	 	this Change Order	 	 	(CO#	 	 	Value)	 
	 	Fixed Costs/Professional Fees

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	Estimated Pass-through Expenses

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	Other Reimbursable Costs/Expenses

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	TOTALS

	 	 	 	 	 	 	 	 	 	 	 	 	 
	 

The following attachments are included as part of this Change Order

Attachment A — Supporting detail of the fees and expenses associated wit the Change in Scope

Attachment B — Revised
Timeline                           o Yes          o No

Attachment C — Revised Payment
Schedule          o Yes          o No

Additional Attachments: [list or state None]

	 	 	 	 	 	 	 
	Corcept Therapeutics Incorporated	 	i3 Research, a division of Ingenix Pharmaceutical

Services (UK) Limited
	 
	 	 	 	 	 	 
	Signature:

	 	 
	 	Signature:
	 	 
	 
	 	 	 	 	 	 
	Name:

	 	 
	 	Name:
	 	 
	 
	 	 	 	 	 	 
	Title:

	 	 
	 	Title:
	 	 
	 
	 	 	 	 	 	 
	Date:

	 	 
	 	Date:
	 	 

16exv10w1

 

Exhibit 10.1

March 17, 2005

Mr. Bruce Besanko

16715 Jackdaw Path

Lakeville, MN 55044

Dear Bruce:

Congratulations! I am pleased to present to you an offer of employment as the Senior Vice
President Finance and Chief Financial Officer within the Executive Team at Yankee Candle Company,
Inc. In this position, you will report directly to Craig Rydin, Chairman and Chief Executive
Officer. As discussed, your employment will commence on Monday, April 4, 2005. .

In specific, your compensation package includes:

	 	 	 	 	 
	

	 	Base Pay:
	 	$6,538.46 per week, an annualized rate of $340,000.00.
	 
	 	 	 	 
	

	 	Target Bonus:
	 	For fiscal 2005 only, we will guarantee an incentive payment of 55% of base
salary actually paid during the applicable fiscal year, subject to the provisions of
the Company’s Management Incentive Plan. The documents related to the Management
Incentive Plan will be provided to you and discussed in detail. Payments in
consideration of the 2005 Management Incentive Plan will be made on or before March 31,
2006.
	 
	 	 	 	 
	

	 	Equity Participation:
	 	You will be awarded a stock option grant that will allow you to
acquire 60,000 shares of common stock. The exercise price for the shares will be the
closing price on the New York Stock Exchange on your employment start date. The stock
option grant vests 25% per year at each anniversary of the grant date. In addition,
you will be awarded 10,000 Performance Shares under Yankee Candle’s 2005 – 2007
Performance Share Plan. The Performance Share plan rewards the attainment of specific
levels of Earnings per Share achievement over the three year cycle. Full details of the
Performance Share will be provided to you and discussed in detail upon your employment.
	 
	 	 	 	 
	

	 	Severance:
	 	Yankee Candle agrees that in the event that your employment is terminated by
Yankee Candle for any reason other than for “Cause,” (as defined in the Company’s most
recent Stock Option and Award Plan) then you shall be paid a lump sum severance payment
in an amount equal to one year of your then current annual base salary, and a pro-rata
portion of your target incentive based upon the effective termination date.
	 
	 	 	 	 
	

	 	Paid Time Off:
	 	You will be eligible for 15 vacation days and 7 Sick/Personal Days
in 2005. You will also be immediately eligible for all holidays as observed by YCC.
	 
	 	 	 	 
	

	 	Executive	 	 
	

	 	Compensation Plan:
	 	As part of our Non-Qualified Deferred Compensation Plan, you are offered
a match on deferral contributions of 100% of your first $10,000

 

 

	 	 	 	 	 
	

	 	 	 	of deferral and 50% of the next $20,000 of deferrals, not to exceed a match of $20,000.
	 
	 	 	 	 
	

	 	Benefits:
	 	You will be eligible for all benefits available to salaried personnel, as more
fully described in the material you have already received.
	 
	 	 	 	 
	

	 	Relocation & Interim Living:	 	 
	 
	 	 	 	 
	

	 	 	 	In addition to the above, Yankee Candle agrees to provide you with a
relocation package. Specifically, Yankee Candle agrees to reimburse :
	 
	 	 	 	 
	

	 	 	 	Home Closing Costs: A real estate commission up to 6% on the
sale of your home (to be grossed up for tax purposes and included in
gross income); points associated with obtaining a mortgage on you new
home to a maximum of two points; usual and customary fees associated
with a real estate attorney and home inspection.
	 
	 	 	 	 
	

	 	 	 	Interim Living Expenses: Expenses for interim living to be
reimbursed by Yankee Candle, for a period not to exceed one hundred
and eighty (180) days. Reimbursable items will include lodging,
meals (except for lunch when working at a YCC location) and laundry.
These expenses will be treated as normal business expenses. Meal
expense is not to exceed $35 per day. In addition, if needed, Yankee
Candle will arrange for a rental car to be used during the interim
living period up to and not to exceed the one hundred and eighty
(180) days.
	 
	 	 	 	 
	

	 	 	 	Home Search Assistance: Home Search Assistance is available
to all new hires/promoted employees and includes information related
to locating real estate services for either renting or purchasing a
home as a part of the relocation.
	 
	 	 	 	 
	

	 	 	 	House Hunting Trips and Return to Former Residence: Yankee
Candle will reimburse for travel expenses related to house hunting
trips and return to former residence during the interim living
period, for a reasonable number of trips, to be mutually agreed upon,
covering a period of time through the end of June 2005. Please note
that certain items may be ineligible for coverage under our plan.
All Travel to be coordinated through PTC, Professional Travel
Corporation.
	 
	 	 	 	 
	

	 	 	 	Movement of Household Goods: Packing, moving, unpacking and
insuring of personal and household goods by public carrier to the new
area of residence or to a storage facility will be reimbursed by
Yankee Candle (from two locations only — point A to point B). This
service will be coordinated through Coldwell Banker. If necessary,
transportation of one vehicle will also be included. Please note that
certain items may be ineligible for coverage under our plan.
	 
	 	 	 	 
	

	 	 	 	Final Family Moving Expenses: Yankee Candle will reimburse
you for living expenses incurred during the actual move from the
former location to the new location. These costs include transportation, lodging en
route and meals. It is the expectation that the final moving period
will not exceed seven (7) days.
	 
	 	 	 	 
	 	 	Relocation and Interim Living expenses are not to exceed a combined total of $175,000, and
are subject to your acceptance of this offer, and your acceptance of the specific terms of
the relocation agreement enclosed.

In this position you are immediately eligible to enroll in our health and wellness benefits (please
see the benefits information packet for further details). Additionally, in accordance with the
Yankee Candle

 

 

Company Inc.’s pay progression plan, your first salary review will occur in January
2006, reviewing your performance for fiscal 2005.

Due to the nature of this position, we do require a signed “Proprietary and Confidential
Information Agreement”, an “Agreement Not to Compete” as well as a signed “Relocation Agreement”.
Please sign and return these documents, as well as a copy of this offer letter, to my personal
attention by March 1, 2005.

We will schedule you to attend Employee Orientation on the Monday your employment begins, April 4,
2005. Employee Orientation will be at the Yankee Candle manufacturing facility at 102 Christian
Lane in Whately, MA (YCI) with a member of the Human Resources Department. Orientation will begin
at 8:30am. Additionally, you will be scheduled to attend Computer Orientation Training immediately
following the Employee Orientation in the Computer Training Room at Yankee Candle Corporate Office
(YCO).

I trust that these conditions of employment are mutually agreed upon and fully understood. If you
have any questions or concerns, please contact me directly. On a personal note, I look forward to
you joining our team, and to working with you!

Warmest regards,

/s/ Martha S. LaCroix

Martha S. LaCroix, SPHR

Senior Vice President, Human Resources

I agree that the terms outlined in this offer of employment are as described to me verbally, and I
do accept these terms. I understand that this is an offer of employment, not an employment
contract, and that employment with Yankee Candle is on an “at will” basis and may be terminated by
me or the Company at any time, for any reason.

Signed:

			
	 	 	 
	/s/ Bruce H. Besanko
	 	March 23, 2005    
	 	 	 
	 
	Bruce H. Besanko
	 	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}]]